Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA. DETAILED ACTION Claims 1-20, 24, 25, 32, 33 and 89 are currently pending in the instant application. Applicants have amended claims 3, 7, 8, 13, 14, 19, 20, 24, 25 and 89 and canceled claims 21-23, 26-31, 34-88 and 90 in an amendment filed on April 3, 2024. Claims 1, 3-5, 8-15 and 89 are rejected and claims 2, 6-7, 16-20, 24, 25, 32, and 33 are objected in this Office Action. I. Priority The instant application claims benefit of US Provisional Application 63/433,824, filed on December 20, 2022. II. Information Disclosure Statement The information disclosure statements (IDS) submitted on April 3, 2024, September 24, 2024, January 16, 2025, May 29, 2025, May 30, 2025, October 2, 2025, January 27, 2026 and March 11, 2026 are in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statements have been considered by the examiner. III. Rejections Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless - (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1 , 3, 4, 5, 8, 9-15 and 89 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Owens , et al. (US 9,688,676) . The instant invention claims The Owens , et al. reference teaches drug formulations that are BTK inhibitors comprising compounds such as (See example 3, column 75 and Tablet Formulation, column 94 ) wherein the ingredients are the following: . This species of the formulation anticipates the genus formulation of the instant invention, wherein the genus formulation is as defined above . I V. Objections Dependent Claim Objections Dependent Claims 2, 6-7, 16-20, 24, 25, 32, and 33 are objected to as being dependent upon a rejected based claim. To overcome this objection, Applicant should rewrite said claims in an independent form and include the limitations of the base claim and any intervening claim. I V. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shawquia Jackson whose telephone number is 571-272-9043. The examiner can normally be reached on 7:00 AM-3:30PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Adam Milligan can be reached on 571-270-7674. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). /SHAWQUIA JACKSON/ Primary Examiner, Art Unit 1626